Nuclear receptors as therapeutic targets for Alzheimer's disease
about
Impact of apolipoprotein E on Alzheimer's diseaseApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse modelsPPAR-γ -- a possible drug target for complicated pregnanciesBezafibrate administration improves behavioral deficits and tau pathology in P301S miceInhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addictionMitochondrial dysfunction in neurodegenerative diseasesDefensive effect of lansoprazole in dementia of AD type in mice exposed to streptozotocin and cholesterol enriched dietInfluence of drug transporters and stereoselectivity on the brain penetration of pioglitazone as a potential medicine against Alzheimer's diseaseNuclear receptors in neurodegenerative diseases.Insulin resistance in Alzheimer's disease.Effects of NR1H3 genetic variation on the expression of liver X receptor α and the progression of Alzheimer's diseaseMicroglia: scapegoat, saboteur, or something else?Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease.Daidzein Augments Cholesterol Homeostasis via ApoE to Promote Functional Recovery in Chronic StrokeMolecular Signaling Mechanisms of Natural and Synthetic Retinoids for Inhibition of Pathogenesis in Alzheimer's Disease.Response to comments on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models"Lentiviral-Mediated Overexpression of the 18 kDa Translocator Protein (TSPO) in the Hippocampal Dentate Gyrus Ameliorates LPS-Induced Cognitive Impairment in Mice.Transcriptional regulation and its misregulation in Alzheimer's disease.Long-term caloric restriction in ApoE-deficient mice results in neuroprotection via Fgf21-induced AMPK/mTOR pathway.Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease.PPARγ recruitment to active ERK during memory consolidation is required for Alzheimer's disease-related cognitive enhancementPioglitazone ameliorates memory deficits in streptozotocin-induced diabetic mice by reducing brain β-amyloid through PPARγ activationThe neuroendocrine control of the innate immune system in health and brain diseases.Receptor-based targeting of therapeutics.Peroxisome proliferator-activated receptors and Alzheimer's disease: hitting the blood-brain barrier.Alzheimer's disease risk alleles in TREM2 illuminate innate immunity in Alzheimer's disease.Novel disease-modifying therapeutics for the treatment of Alzheimer's disease.Anti-neuroinflammatory agents for the treatment of Alzheimer's disease.Hypercholesterolaemia-induced oxidative stress at the blood-brain barrier.The emerging role of bexarotene in the treatment of Alzheimer's disease: current evidence.Involvement of inflammation in Alzheimer's disease pathogenesis and therapeutic potential of anti-inflammatory agents.EFAD transgenic mice as a human APOE relevant preclinical model of Alzheimer's disease.Regulation of behaviour by the nuclear receptor TLX.Development of Cerebral Microbleeds in the APP23-Transgenic Mouse Model of Cerebral Amyloid Angiopathy-A 9.4 Tesla MRI Study.NR4A nuclear receptors support memory enhancement by histone deacetylase inhibitors.A randomized controlled study to evaluate the effect of bexarotene on amyloid-β and apolipoprotein E metabolism in healthy subjectsTargeting Neuroinflammation to Treat Alzheimer's Disease.PPARδ activation by bexarotene promotes neuroprotection by restoring bioenergetic and quality control homeostasis.The Continuing Failure of Bexarotene in Alzheimer's Disease Mice.Changes in the expression of genes related to neuroinflammation over the course of sporadic Alzheimer's disease progression: CX3CL1, TREM2, and PPARγ.
P2860
Q24567759-BFAB2700-B518-4057-A149-84CAD7667E6BQ24628845-04D8E14D-74EC-40D8-9E6B-9F9468D9838DQ26863678-01F20BEC-1804-47C7-81DA-6A705853450AQ28273620-5648D086-0A84-4589-A38B-6CEF4E032523Q28283718-767F50E2-5CE0-4041-8438-F8221DDB591DQ28387647-01FF1D48-D6D9-426D-A6C8-20C969ED0ECAQ28535014-F9D8B14F-C18C-4FB6-9AAD-D711BB90DAD0Q33562308-B4FA8883-8150-4D20-B82A-717DF322E3A7Q34580020-C3E8755C-0FA2-4A08-88FA-85108CF8F4F2Q34622157-5476FDDF-F635-4D54-9E46-12247E665869Q35053654-71CEA289-E414-4304-AFD9-28EB05D115EEQ35606301-A81A9067-B203-4D20-9189-B5BF1FECEC21Q36208400-F41E64EE-E5A6-4FAD-BA6A-4E92033236FCQ36272544-8E978919-36F0-4CE2-9463-7C2761E13E75Q36771721-40943C9C-A111-407F-AC8C-E11A47331FBCQ37022972-804E1E66-3D2C-4487-8448-E70E2C96BF16Q37346461-4F05889B-B685-4642-9FA6-2B22C2E49A6CQ37370537-1D3EBECE-E476-4939-8736-E1C9291D8EC5Q37538200-06E29065-AE29-4E0B-8BA8-C6502A3E1318Q37559812-A549ADC0-E6BF-49E2-9AE6-4DD578D16342Q37633627-A7238D70-5C50-4B79-9701-3320213BBCA5Q37728905-A56B8850-9875-4DAB-A468-9C51E78D7A38Q38020956-937B6E2E-57C9-45C8-82BF-750559A3E7BDQ38084739-DB4E57A8-B8CA-4410-BDC9-49DFE19998E5Q38089668-4C1EDAE9-DAA0-4610-B3E6-3E1647551FBDQ38108433-10F050BC-B437-4B3D-9B40-498677376C2FQ38127470-A8C84EEA-F97E-4D7D-B6B2-9FB7BD5A5C98Q38136313-2D411596-755B-4190-99CB-266263BE1D63Q38238644-0EC6C1DF-E17E-4AA4-89A9-06D7472C897DQ38364682-12C9F5C0-860F-4460-92E4-7342F1E65368Q38569669-5CB22CB6-D94F-4FA5-BD4A-7CCA27F84E58Q38733357-9DA8F8C1-7EAC-4526-B742-A5B0608945C9Q38993454-EDB2902A-140B-426B-AFE4-19E11FE9A263Q42095705-2C25F6A6-4D4D-4D44-91FF-A7DC10D70878Q42536118-46401703-4D83-4AFA-A78D-81D75921FE18Q42689665-1859D7B2-DAAA-4F92-9234-33210E4C8270Q47188911-25C9ADD3-EFBF-4A40-BE4C-0BE63BB60EE6Q47322495-EFE2DB15-BE45-42EE-9F40-B55857EC6989Q47570646-7AB9955E-F136-4F1B-A082-9AE1EB4215A6Q48372341-5BBC484B-EEB2-48BA-89C4-7F02AD058125
P2860
Nuclear receptors as therapeutic targets for Alzheimer's disease
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Nuclear receptors as therapeutic targets for Alzheimer's disease
@ast
Nuclear receptors as therapeutic targets for Alzheimer's disease
@en
type
label
Nuclear receptors as therapeutic targets for Alzheimer's disease
@ast
Nuclear receptors as therapeutic targets for Alzheimer's disease
@en
prefLabel
Nuclear receptors as therapeutic targets for Alzheimer's disease
@ast
Nuclear receptors as therapeutic targets for Alzheimer's disease
@en
P2860
P1476
Nuclear receptors as therapeutic targets for Alzheimer's disease
@en
P2093
Gary E Landreth
Shweta Mandrekar-Colucci
P2860
P304
P356
10.1517/14728222.2011.594043
P407
P577
2011-07-01T00:00:00Z